HemaSphere (Jun 2022)

P368: A PHASE II STUDY OF INOTUZUMAB OZOGAMICIN FOR THE TREATMENT OF MEASURABLE RESIDUAL DISEASE-POSITIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

  • J. Senapati,
  • H. Kantarjian,
  • N. Short,
  • Y. Alvarado,
  • J. Burger,
  • N. Jain,
  • M. Konopleva,
  • F. Ravandi,
  • C. DiNardo,
  • L. Masarova,
  • K. Sasaki,
  • P. A. Thompson,
  • A. Ferrajoli,
  • J. O. Jacob,
  • E. D. Mayor,
  • A. M. Milton,
  • C. Loiselle,
  • R. S. Garris,
  • E. J. Jabbour

DOI
https://doi.org/10.1097/01.HS9.0000844360.06367.63
Journal volume & issue
Vol. 6
pp. 268 – 269

Abstract

Read online

No abstracts available.